Logo
Logo

About Palbociclib API

Product
  • Therapeutic Category抗癌 / 肿瘤学

  • CAS Number

    571190-30-2

  • API Technology

    Synthetic

  • Dose Form

    Capsule/ Tablet, Oral Solids

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    Brazil DMF, USDMF, Singapore DMF

Mechanism of Action

It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.

Indication

IBRANCE is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

  • An aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
  • Fulvestrant in women with disease progression following endocrine therapy.

Related APIs

恩扎卢胺

抗癌 / 肿瘤学

arrow

Adagrasib

抗癌 / 肿瘤学

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.